Record Information |
---|
Version | 5.0 |
---|
Status | Expected but not Quantified |
---|
Creation Date | 2012-09-06 15:16:50 UTC |
---|
Update Date | 2022-03-07 02:51:42 UTC |
---|
HMDB ID | HMDB0014660 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Trandolapril |
---|
Description | Trandolapril is a non-sulhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to its biologically active diacid form, trandolaprilat, in the liver. Trandolaprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Trandolapril may be used to treat mild to moderate hypertension, to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction, as an adjunct treatment for congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. |
---|
Structure | [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1 |
---|
Synonyms | Value | Source |
---|
Mavik | Kegg | Abbott brand OF trandolapril | HMDB | Aventis brand OF trandolapril | HMDB | Gopten | HMDB | Alter brand OF trandolapril | HMDB | 1-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-1H-indol-2-carboxylic acid | HMDB | Aventis pharma brand OF trandolapril | HMDB | Hoechst brand OF trandolapril | HMDB | Odrik | HMDB | Udrik | HMDB | Knoll brand OF trandolapril | HMDB |
|
---|
Chemical Formula | C24H34N2O5 |
---|
Average Molecular Weight | 430.5372 |
---|
Monoisotopic Molecular Weight | 430.246772208 |
---|
IUPAC Name | (2S,3aR,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid |
---|
Traditional Name | trandolapril |
---|
CAS Registry Number | 87679-37-6 |
---|
SMILES | [H][C@@]12C[C@H](N(C(=O)[C@H](C)N[C@@H](CCC3=CC=CC=C3)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O |
---|
InChI Identifier | InChI=1S/C24H34N2O5/c1-3-31-24(30)19(14-13-17-9-5-4-6-10-17)25-16(2)22(27)26-20-12-8-7-11-18(20)15-21(26)23(28)29/h4-6,9-10,16,18-21,25H,3,7-8,11-15H2,1-2H3,(H,28,29)/t16-,18+,19-,20-,21-/m0/s1 |
---|
InChI Key | VXFJYXUZANRPDJ-WTNASJBWSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as dipeptides. These are organic compounds containing a sequence of exactly two alpha-amino acids joined by a peptide bond. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organic acids and derivatives |
---|
Class | Carboxylic acids and derivatives |
---|
Sub Class | Amino acids, peptides, and analogues |
---|
Direct Parent | Dipeptides |
---|
Alternative Parents | |
---|
Substituents | - Alpha-dipeptide
- Alpha-amino acid ester
- N-acyl-l-alpha-amino acid
- N-acyl-alpha-amino acid
- N-acyl-alpha amino acid or derivatives
- Alpha-amino acid amide
- Alpha-amino acid or derivatives
- Indole or derivatives
- N-acylpyrrolidine
- Pyrrolidine carboxylic acid
- Pyrrolidine carboxylic acid or derivatives
- Fatty acid ester
- Aralkylamine
- Monocyclic benzene moiety
- Dicarboxylic acid or derivatives
- Benzenoid
- Fatty acyl
- Pyrrolidine
- Tertiary carboxylic acid amide
- Amino acid or derivatives
- Carboxamide group
- Carboxylic acid ester
- Amino acid
- Azacycle
- Secondary aliphatic amine
- Carboxylic acid
- Organoheterocyclic compound
- Secondary amine
- Hydrocarbon derivative
- Amine
- Organopnictogen compound
- Organic oxygen compound
- Carbonyl group
- Organic oxide
- Organic nitrogen compound
- Organooxygen compound
- Organonitrogen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 119 - 123 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | 0.021 g/L | Not Available | LogP | 3.5 | Not Available |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross SectionsAdduct Type | Data Source | CCS Value (Å2) | Reference |
---|
[M+H]+ | CBM | 203.5 | 30932474 |
|
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
Trandolapril,1TMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1[C@H](C(=O)O[Si](C)(C)C)C[C@H]2CCCC[C@@H]21 | 3086.3 | Semi standard non polar | 33892256 | Trandolapril,1TMS,isomer #2 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21)[Si](C)(C)C | 3126.4 | Semi standard non polar | 33892256 | Trandolapril,2TMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1[C@H](C(=O)O[Si](C)(C)C)C[C@H]2CCCC[C@@H]21)[Si](C)(C)C | 3121.4 | Semi standard non polar | 33892256 | Trandolapril,2TMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1[C@H](C(=O)O[Si](C)(C)C)C[C@H]2CCCC[C@@H]21)[Si](C)(C)C | 3112.6 | Standard non polar | 33892256 | Trandolapril,2TMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1[C@H](C(=O)O[Si](C)(C)C)C[C@H]2CCCC[C@@H]21)[Si](C)(C)C | 4195.9 | Standard polar | 33892256 | Trandolapril,1TBDMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N1[C@H](C(=O)O[Si](C)(C)C(C)(C)C)C[C@H]2CCCC[C@@H]21 | 3315.0 | Semi standard non polar | 33892256 | Trandolapril,1TBDMS,isomer #2 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@H]2CCCC[C@@H]21)[Si](C)(C)C(C)(C)C | 3365.1 | Semi standard non polar | 33892256 | Trandolapril,2TBDMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1[C@H](C(=O)O[Si](C)(C)C(C)(C)C)C[C@H]2CCCC[C@@H]21)[Si](C)(C)C(C)(C)C | 3559.5 | Semi standard non polar | 33892256 | Trandolapril,2TBDMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1[C@H](C(=O)O[Si](C)(C)C(C)(C)C)C[C@H]2CCCC[C@@H]21)[Si](C)(C)C(C)(C)C | 3505.2 | Standard non polar | 33892256 | Trandolapril,2TBDMS,isomer #1 | CCOC(=O)[C@H](CCC1=CC=CC=C1)N([C@@H](C)C(=O)N1[C@H](C(=O)O[Si](C)(C)C(C)(C)C)C[C@H]2CCCC[C@@H]21)[Si](C)(C)C(C)(C)C | 4313.3 | Standard polar | 33892256 |
|
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Trandolapril GC-MS (Non-derivatized) - 70eV, Positive | splash10-001l-9134000000-c52f8386e44b6f3e4183 | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Trandolapril GC-MS (1 TMS) - 70eV, Positive | splash10-004i-4112900000-5696f5c17973fe4d225b | 2017-10-06 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Trandolapril GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trandolapril 10V, Positive-QTOF | splash10-001i-0344900000-99ab1a9e9945717fb390 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trandolapril 20V, Positive-QTOF | splash10-001l-3892000000-2c1c412e4f9f90ca78ab | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trandolapril 40V, Positive-QTOF | splash10-01wf-2920000000-549eb411c184d9623926 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trandolapril 10V, Negative-QTOF | splash10-005i-1009500000-13932e1c6beeefa44a68 | 2016-08-04 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trandolapril 20V, Negative-QTOF | splash10-00ks-2529200000-a0a12c08cda6be722cf4 | 2016-08-04 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trandolapril 40V, Negative-QTOF | splash10-01ba-3911000000-6f9e1a5a81f4539f8f44 | 2016-08-04 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trandolapril 10V, Negative-QTOF | splash10-004i-0001900000-1d6328b40cc6fc4cd692 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trandolapril 20V, Negative-QTOF | splash10-014i-2966200000-6647aa4aadfe2af7c9d3 | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trandolapril 40V, Negative-QTOF | splash10-0329-0900100000-32685cedae485e671c9f | 2021-09-23 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trandolapril 10V, Positive-QTOF | splash10-053r-0115900000-e1046071e0edb6b7cd2d | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trandolapril 20V, Positive-QTOF | splash10-03dl-2933100000-1522daaf764576e88653 | 2021-09-25 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Trandolapril 40V, Positive-QTOF | splash10-00kf-5900000000-b61562d820bcec79a11c | 2021-09-25 | Wishart Lab | View Spectrum |
|
---|
General References | - Zannad F: Trandolapril. How does it differ from other angiotensin converting enzyme inhibitors? Drugs. 1993;46 Suppl 2:172-81; discussion 182. [PubMed:7512472 ]
- Wiseman LR, McTavish D: Trandolapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs. 1994 Jul;48(1):71-90. [PubMed:7525196 ]
- Jouquey S, Stepniewski JP, Hamon G: Trandolapril dose-response in spontaneously hypertensive rats: effects on ACE activity, blood pressure, and cardiac hypertrophy. J Cardiovasc Pharmacol. 1994;23 Suppl 4:S16-8. [PubMed:7527096 ]
- Conen H, Brunner HR: Pharmacologic profile of trandolapril, a new angiotensin-converting enzyme inhibitor. Am Heart J. 1993 May;125(5 Pt 2):1525-31. [PubMed:8480624 ]
- Sanbe A, Tanonaka K, Kobayasi R, Takeo S: Effects of long-term therapy with ACE inhibitors, captopril, enalapril and trandolapril, on myocardial energy metabolism in rats with heart failure following myocardial infarction. J Mol Cell Cardiol. 1995 Oct;27(10):2209-22. [PubMed:8576937 ]
- Authors unspecified: Trandolapril: an ACE inhibitor for treatment of hypertension. Med Lett Drugs Ther. 1996 Nov 22;38(988):104-5. [PubMed:8941256 ]
- Torp-Pedersen C, Kober L: Effect of ACE inhibitor trandolapril on life expectancy of patients with reduced left-ventricular function after acute myocardial infarction. TRACE Study Group. Trandolapril Cardiac Evaluation. Lancet. 1999 Jul 3;354(9172):9-12. [PubMed:10406358 ]
- Guay DR: Trandolapril: a newer angiotensin-converting enzyme inhibitor. Clin Ther. 2003 Mar;25(3):713-75. [PubMed:12852701 ]
- Reynolds NA, Wagstaff AJ, Keam SJ: Trandolapril/verapamil sustained release: a review of its use in the treatment of essential hypertension. Drugs. 2005;65(13):1893-914. [PubMed:16114984 ]
- Rubio-Guerra AF, Vargas-Robles H, Vargas-Ayala G, Rodriguez-Lopez L, Escalante-Acosta BA: The effect of trandolapril and its fixed-dose combination with verapamil on circulating adhesion molecules levels in hypertensive patients with type 2 diabetes. Clin Exp Hypertens. 2008 Oct;30(7):682-8. doi: 10.1080/10641960802251941. [PubMed:18855271 ]
- Berl T: Review: renal protection by inhibition of the renin-angiotensin-aldosterone system. J Renin Angiotensin Aldosterone Syst. 2009 Mar;10(1):1-8. doi: 10.1177/1470320309102747. [PubMed:19286752 ]
- Diaz A, Ducharme A: Update on the use of trandolapril in the management of cardiovascular disorders. Vasc Health Risk Manag. 2008;4(6):1147-58. [PubMed:19337528 ]
|
---|